SMP 300

Drug Profile

SMP 300

Latest Information Update: 14 Feb 2006

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Class Ischaemic heart disorder therapies
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Angina pectoris; Myocardial infarction

Most Recent Events

  • 14 Feb 2006 No development reported - Preclinical for Myocardial infarction in Japan (PO)
  • 14 Feb 2006 No development reported - Preclinical for Angina pectoris in Japan (PO)
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top